Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Media and Investors Resources
Press Release, 19 November 2019
Extraordinary General Meeting of Kuros Biosciences approves all resolutions
Press Release, 19 November 2019
Kuros announces the terms of the proposed capital increase through a discounted rights offering expected to raise up to CHF 12 million gross proceeds for the commercialization of its products and the further development of its product candidates
Press Release, 29 October 2019
Kuros convenes Extraordinary General Meeting
Press Release, 2 October 2019
Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advanced Bone Graft MagnetOs
Press Release, 24 September 2019
Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North American Spine Society 34 th Annual Meeting
Press Release, 3 September 2019
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion